Condition: Giant Cell Arteritis · Sponsor: Insel Gruppe AG, University Hospital Bern
The goal of this open-label clinical trial is to evaluate the efficacy of AzaFol-PET/CT in the diagnosis of GCA (giant cell arteritis), to compare AzaFol- with 2-\[18F\]FDG-PET/CT, and to assess the safety and tolerability of AzaFol in subjects with suspicion of GCA. Participants will undergo AzaFol-PET/CT imaging at a single timepoint.
This description comes directly from the study's public registry record.
Britta Maurer · +41 31 63 2 7229 · RI-Studien@insel.ch
Always discuss trial participation with your own doctor first.
| Department of Rheumatology and Immunology, University Hospital Bern, Inselspital | Bern, Switzerland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06335888